NeoTCR-T Platform - T Cells with Tumor Neoantigen-specific T Cell Receptors

Based on its advanced neoantigen prediction platform and in vitro evaluation platform, Creative Biolabs has continued to build a TCR-T therapy that can target tumor-specific neoantigen, which will become a major weapon for cancer treatment.

TCR-T Therapy

TCR-T therapy is a type of adoptive cell transfer therapy (ACT), which improves the recognition of tumor-associated antigens by T cell receptors (TCRs) through transducing chimeric antigen receptors or TCRα/β heterodimers, and enhances affinity of TCRs to tumor antigens and strengthens T cells’ lethality to tumor cells. By infusion of genetically modified T cells that can efficiently identify tumor-specific targets, TCR-T therapy gives the immune system new, unnatural immune activity. In addition to being able to kill tumors as quickly as chemotherapy and targeted therapy, TCR-T therapy can avoid the delayed effects of cancer vaccines and immune checkpoint therapies.

NeoTCR-T Platform - Confer T Cells Ability to Specifically Target Tumor Cells

The general steps of TCR-T therapy are: first identify one or more tumor antigens as therapeutic targets, and then obtain TCR sequences that specifically recognize tumor antigens; then use genetic engineering techniques to introduce the antigen-specific TCR gene sequence in patient-derived T cells, TCR-T cells that specifically recognize tumor antigens are thus obtained. These TCR-T cells are expanded in vitro and then reinfused to patients to kill tumor cells. At present, the clinical effectiveness of TCR-T therapy is still relatively low, and the bottlenecks that limit its effectiveness are mainly the search for effective high-affinity tumor target antigen TCR and the improvement of TCR-T construction and preparation efficiency. Creative Biolabs' NeoTCR-T platform solves these two problems well and greatly accelerates the clinical conversion application and efficiency of TCR-T therapy.

Flow of T cell transfer therapy with tumor neoantigen-specific TCR based on SpecificallyNeoTCR-T platform. - Creative Biolabs

The NeoTCR-T platform is based on the fruits of the advanced neoantigen prediction platform and neoantigen in vitro evaluation platform that we developed, making the production of personalized TCR-T products against tumor neoantigen a reality. The NeoTCR-T platform can also be designed to prepare T cells that recognize tumor cells with high specificity and high affinity, making up for the short board of the universal TCR-T targeting the widely existing TAAs, and after modification, we can make NeoTCR-T recognizes more targets and further enhances its scope of application and lethality.

Strengths of NeoTCR-T Platform

Simplicity of T cell expansion in vitro
Multi-target design on one T cell allows it to combat multiple epitopes
Flexibility-can be genetically modified to endow it with new capabilities
Development of plug-and-play products through allogeneic T cell preparation
High specificity for tumor cells and enhanced lethality
Unique technology makes the construction and preparation time of TCR-T greatly shortened

Creative Biolabs' top tumor research experts collaborated with our immunology experts and artificial intelligence experts to not only develop high-precision neoantigen prediction algorithms and supporting in vitro evaluation platforms, but also develop improved TCR-T therapy with highly specific tumor antigen recognition based on these two technologies.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.